Compare CPK & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPK | VERA |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 1995 | 2021 |
| Metric | CPK | VERA |
|---|---|---|
| Price | $124.40 | $38.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $140.00 | $81.30 |
| AVG Volume (30 Days) | 118.8K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ 13.50 | N/A |
| EPS | ★ 5.97 | N/A |
| Revenue | ★ $930,000,000.00 | N/A |
| Revenue This Year | $5.02 | N/A |
| Revenue Next Year | $5.26 | $416.83 |
| P/E Ratio | $20.81 | ★ N/A |
| Revenue Growth | ★ 18.14 | N/A |
| 52 Week Low | $115.24 | $18.53 |
| 52 Week High | $140.59 | $56.05 |
| Indicator | CPK | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 42.17 |
| Support Level | $123.24 | $37.36 |
| Resistance Level | $126.05 | $43.21 |
| Average True Range (ATR) | 2.95 | 2.33 |
| MACD | -0.71 | 0.10 |
| Stochastic Oscillator | 20.58 | 25.09 |
Chesapeake Utilities Corp is a diversified energy delivery company that is engaged in natural gas transmission and distribution, electricity generation and distribution, propane gas distribution, mobile compressed natural gas utility services and solutions and other businesses. The company operates in two reportable segments, Regulated Energy and Unregulated Energy. The company's natural gas and electric distribution operations in Delaware, Maryland and Florida are subject to regulation by PSC. Eastern Shore, its natural gas transmission is subject to regulation by the FERC and Peninsula Pipeline and Aspire Energy Express, its intrastate pipeline subsidiaries, are subject to regulation by the Florida PSC and Public Utilities Commission of Ohio, respectively.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.